Low-dose whole-brain radiation with a device in mild Alzheimer's disease dementia
Tests low-dose brain radiation against a sham procedure in people with mild Alzheimer's dementia.
Key facts
- Who runs it
- ReadyCure Inc.
- Where
- Cheonan, South KoreaSee the site
- Trial code
- Registry title
- Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients With Mild Alzheimer's Disease Dementia
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 26 Oct 2026
- Expected to end
- 30 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- HeLaXON 1X Low-Dose Radiation Therapy
- Sham HeLaXON 1X Procedure
- Record updated
- 7 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 60 to 85 with mild Alzheimer's disease dementia and amyloid in the brain. Half get low-dose whole-brain radiation, half a sham procedure.
- Age
- 60 to 85 years
- Sex
- Men and women can join.
- Disease stage
- Mild Alzheimer's disease dementia (Stage 4). K-MMSE-2 score of 20 to 26. CDR Global Score of 1, or 0.5 or 1 with a CDR-SB score of 4.5 to 9.0.
- Earlier treatment
- If taking donepezil, galantamine or rivastigmine, the dose must have been stable for at least 12 weeks. No earlier radiation therapy to the brain.
- Biomarker or test result
- Amyloid in the brain confirmed by amyloid PET.
Main reasons for not taking part
- Earlier radiation therapy to the brain
- Seizure within the last 10 years
- Cancer diagnosed within 5 years or under cancer treatment
- Pregnant or breastfeeding
- Memory problems caused by another condition, such as stroke or Lewy body dementia
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Male or female participants aged 60 to 85 years, inclusive
- Mild dementia (Stage 4) according to the NIA-AA (New Diagnostic Criteria for Alzheimer's Disease) criteria
- At screening, participants must meet all of the following criteria:; K-MMSE-2 score of 20 to 26, inclusive; CDR Global Score of 1, or CDR Global Score of 0.5 or 1 with a CDR-SB score of 4.5 to 9.0, inclusive; Memory Box Score of at least 0.5
- If receiving a cholinesterase inhibitor (donepezil, galantamine, or rivastigmine) for symptomatic treatment, the participant must have been maintained on a stable dose for at least 12 weeks before the screening visit
- Positive cerebral amyloid accumulation confirmed by amyloid PET
- Able to undergo the cognitive assessments and imaging examinations required by the study
- Has a caregiver who can provide information regarding the participant's overall condition and changes in cognitive and functional status
- Written informed consent for study participation must be obtained from a legally authorized representative. If, based on the investigator's assessment of decision-making capacity, the participant is considered able to understand the purpose and procedures of the study and voluntarily express his or her wishes, written informed consent will also be obtained from the participant
Who cannot take part
- History of prior radiation therapy to the brain. 2. History of seizure within 10 years before the screening date. 4. Presence of a scalp skin disorder. 5. History of hypersensitivity to Vizamyl™ (flutemetamol F 18 injection) or any of its major excipients, including polysorbate 80; Contraindication to MRI, including but not limited to a pacemaker, metallic implant, or severe claustrophobia that prevents MRI examination
- Diagnosis of a malignant tumor within 5 years before the screening visit or currently receiving treatment for a malignancy
- Pregnant or breastfeeding. 8. Previous treatment with an anti-amyloid monoclonal antibody without an interval of at least 5 half-lives before the screening visit
- Clinically significant unstable psychiatric disorder, including uncontrolled depression, schizophrenia, or bipolar disorder, diagnosed within 6 months before screening
- Prior macrohemorrhage greater than 1 cm in diameter on T2-weighted imaging, or prior subarachnoid hemorrhage, unless it can be documented that the finding is not due to an underlying structural or vascular abnormality and does not suggest a risk of recurrent hemorrhage
- Any MRI finding that, in the opinion of the investigator, may contribute to the participant's dementia, pose a risk to the participant, or prevent satisfactory MRI assessment for safety monitoring; Participation in another interventional clinical trial at screening with receipt of an investigational drug or application of an investigational medical device; Any other clinically significant finding that, in the investigator's judgment, makes the participant unsuitable for study participation; Unwilling or unable to use at least one medically acceptable method of contraception throughout the study
- Cognitive impairment attributable to a condition other than Alzheimer's disease, including drug-related causes or other neurological or neurodegenerative conditions such as substance abuse, vitamin B12 deficiency, thyroid dysfunction, stroke or other cerebrovascular disease, Lewy body dementia, frontotemporal dementia, or traumatic brain injury
- Acute or subacute hemorrhage
- Diffuse white matter disease defined as a score of 3 on the age-related white matter changes scale
- Any of the following findings on brain MRI:
- More than 4 microhemorrhages
- Cortical infarct greater than 1.5 cm in diameter, irrespective of anatomical location
- More than 1 lacunar infarct greater than 1.5 cm in diameter
- Superficial siderosis
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 60 and 85 years old?
Where in South Korea
- Soonchunhyang University Cheonan HospitalCheonan, South KoreaContact: InYoung Jo, PhDTaking people
About the trial
What the trial wants to find out
This randomized, sham-controlled, exploratory clinical trial will evaluate the efficacy and safety of HeLaXON, an investigational low-dose radiation therapy device, in patients with mild Alzheimer's disease dementia. A total of 30 participants will be randomly assigned in a 1:1 ratio to receive either low-dose whole-brain radiation therapy or a sham procedure using the same device. Participants in the treatment group will receive 0.04 Gy per session twice weekly for 3 weeks, for a total of 6 sessions and a cumulative dose of 0.24 Gy. Participants in the sham group will undergo the same device procedures without radiation delivery. Participants and outcome assessors will remain blinded to treatment assignment. Changes in cognitive function, dementia severity, daily functioning, and amyloid burden will be evaluated at 6 and 12 months after treatment. Safety will be assessed throughout the study. Exploratory blood biomarkers, including plasma Aβ42/40 ratio, p-tau217, and Aβ oligomer, will also be evaluated.
The 2 groups in the trial
- HeLaXON 1X Low-Dose Whole-Brain Radiation TherapyTreatment being tested
Participants will receive low-dose whole-brain radiation therapy using HeLaXON 1X at a dose of 0.04 Gy per session, twice weekly for 3 weeks, for a total of 6 sessions and a cumulative dose of 0.24 Gy.
Treatment: HeLaXON 1X Low-Dose Radiation Therapy
- Sham HeLaXON 1X ProcedureSham treatment, for comparison
Participants will undergo the same HeLaXON 1X procedures as the experimental group, including treatment positioning, head and neck immobilization, device operation, sound, and lighting, but no radiation will be delivered (0.00 Gy).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Single-Center, Randomized, Subject-Assessor Double-Blind, Sham-Controlled, Exploratory Clinical Trial to Evaluate the Pre- and Post-Treatment Changes of HeLaXON, a Low-Dose Radiation Therapy Device, in Patients With Mild AD Dementia
- Plain-language title
- Low-dose whole-brain radiation with a device in mild Alzheimer's disease dementiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07863011, who can take part
- Record updated
- 7 October 2026